Table 1.
Unit costs.
Table 2.
Baseline patient characteristics at randomization.
Table 3.
Incremental cost-effectiveness results of cast treatment compared with surgery (surgery as reference).
Table 4.
Mean costs per cost category (€, per patient).
Fig 1.
Cost-effectiveness analyses for PRWE (societal perspective).
(a) Cost-effectiveness plane with incremental costs (€) on the y-axis and incremental effects (ΔPRWE) on the x-axis; dots represent bootstrap replications and the red dot the mean; the dashed line marks the non-inferiority margin (14 PRWE points). (b) Cost-effectiveness acceptability curve (CEAC) for superiority, showing the probability that cast treatment is cost-effective across willingness-to-pay thresholds. (c) CEAC for non-inferiority, showing the probability that cast treatment is non-inferior to surgery across willingness-to-pay thresholds.
Fig 2.
Cost-effectiveness analyses for QALYs (societal perspective).
(a) Cost-effectiveness plane with incremental costs (€) on the y-axis and incremental effects (ΔQALYs) on the x-axis; dots represent bootstrap replications and the red dot the mean; the dashed line marks the non-inferiority margin (0.074 QALYs). (b) Cost-effectiveness acceptability curve (CEAC) for superiority, showing the probability that cast treatment is cost-effective across willingness-to-pay thresholds (€/QALY gained). (c) CEAC for non-inferiority, showing the probability that cast treatment is non-inferior to surgery across willingness-to-pay thresholds.